AP27509399 “Study on the effect of exosomes from preconditioned human umbilical cord mesenchymal stem cells in the treatment of atherosclerosis”

Relevance

Atherosclerosis (AS) is a common vascular disease, which is based on the presence of lipid plaques in the vascular endothelium, with consequences associated with insufficient blood supply to organs and tissues. This disease affects 17.8% of the population in the world and 22.4% in Kazakhstan. Premature mortality of the population and consequences in the form of cardiovascular diseases, as well as early disability necessitate the search for new approaches to its treatment. Many studies in preclinical models of atherosclerosis demonstrate the significant potential of mesenchymal stem cells (MSCs) in inhibiting the development of atherosclerosis and their immunosuppressive, regenerative and atheroprotective effect of MSCs on atherosclerotic lesions of the vascular endothelium. The use of exosomes isolated from mesenchymal stem cells from various sources has significant potential in the treatment of atherosclerosis.

The goal 

The goal of the project is to investigate the effect of exosomes isolated from cytokine-preconditioned human umbilical cord mesenchymal stem cells on an experimental animal with induced atherosclerosis.

Expected Results

1. The culture of human umbilical cord MSCs will be isolated and characterized.

2. Exosomes from human umbilical cord MSCs (hUC-MSCs) will be isolated and characterized.

3. The optimal cytokines and preconditioning period for effectively enhancing the immunomodulatory properties of hUC-MSCs and their exosomes in vitro will be determined.

4. In vivo studies will be conducted on a mouse model with induced atherosclerosis to determine the therapeutic effect of exosomes from cytokine-preconditioned hUC-MSCs.

Project leader

Sekenova Aliya – Scopus ID – 57218821100

Орындаушылар

  1. Issabekova Assel ORCID ID – 0000-0002-8844-2510
  2. Shahatbayev Miras
  3. Alymbek Symbat

Publications and security documents

  1. Sekenova A, Li Y, Issabekova A, Saparov A, Ogay V. TNF-α Preconditioning Improves the Therapeutic Efficacy of Mesenchymal Stem Cells in an Experimental Model of Atherosclerosis. Cells. 2023 Sep 13;12(18):2262. doi: 10.3390/cells12182262. PMID: 37759485; PMCID: PMC10526914.IF-6.0, Q1, Percentile 84, Cite Score 9.9.
  2. Ogay V, Sekenova A, Li Y, Issabekova A, Saparov A. The Therapeutic Potential of Mesenchymal Stem Cells in the Treatment of Atherosclerosis. Curr Stem Cell Res Ther. 2021;16(7):897-913. doi: 10.2174/1574888X16999210128193549. PMID: 33511957.IF 2.614, Percentile 72, Q2, Cite Score 4.9.
  3. Sekenova A, Ogay V. Role of mesenchymal stem cells in the regulation of immune response. Bull Gumilyov Eurasian Natl Univ. Biosci Ser. 2018, № 2(123):69–83. (ККСОН РК)
  4. Ogay V.B., Sekenova А.Е., Li Е.А. Method for preconditioning of mesenchymal stem cells to enhance their anti-inflammatory properties. Patent № 35174. Date of Issue 02.07.2021